Open in interactive viewer → charts, metric popovers & call review

Avicanna's First Profit Is a Tax Credit Wearing a Turnaround's Coat

Adjusted EBITDA turns positive at $222K — but a $348K SR&ED refund, a 13% debenture, and an all-time-low share price tell the more honest story
AVCN.TO · Earnings Call · 2026-11-12

A profit, with a footnote

Avicanna is an $8 million market-cap company that just turned ten years old, and it chose the occasion to deliver the number it has dangled in front of shareholders for years: a positive adjusted EBITDA. The figure was small — $222,000 for the third quarter of 2026 — but the framing was not. “Adjusted EBITDA was positive $222,000 for the quarter, an improvement of $1 million year-over-year and $577,000 from the second quarter of 2026.” — Nick Hilborn, Chief Financial Officer · 2026-11-12 Operating loss narrowed 18% year-over-year, net loss before tax shrank to $301,000 from $1.4 million, and revenue of $5.7 million was down 10% year-over-year but up 2% sequentially. Gross margin edged from 49% to 51%. Now the footnote, which management supplied itself. The bridge to that profit leaned heavily on a government cheque: “The remaining savings are attributed to a refundable scientific research and experimental development, or SR&ED, tax credit of $348,000.” — Nick Hilborn, Chief Financial Officer · 2026-11-12 Read those two sentences together and the headline dissolves. The credit is larger than the entire adjusted EBITDA it helped produce — strip it out and the quarter is still a loss-making one, just a smaller one. To be fair, the credit is not a fraud; the Canadian government extended SR&ED eligibility to public companies in 2026, and this is a genuinely new, repeatable mechanism for a company that had been excluded since its IPO. But an investor buying "first profit" is buying a policy change plus two-thirds of a cost-cutting program, not an operating inflection.

RHO Phyto exits, QUIX enters

The most telling detail in this quarter is a keyword that isn't there. RHO Phyto was the company's #2 talking point in the 2023 fourth quarter, again in the 2025 first quarter, and again as recently as the 2026 first quarter — the branded flag the whole product story was carried under. It has vanished from the current top-30 entirely. In its place: the QUIX portfolio, fast onset formulations, capsules, gummies, tablets. A flagship brand was retired on the quiet and replaced by a platform name. That is a real hand-off, not a marketing shuffle. QUIX is a nano-emulsion delivery technology the company developed internally, patents filed, designed to shrink cannabinoid onset from the typical 90-plus minutes down toward a quarter of an hour. “This technology is designed to deliver and have onset much faster within a 15- to 20-minute window.” — Aras Azadian, Founding CEO · 2026-11-12 The strategic logic is explicitly aimed at combustible products — the CEO argues inhalation persists mostly because oral products are too slow, and that a fast oral alternative widens the addressable market beyond existing cannabinoid patients. Ten SKUs launched late in Q3, roughly 33 planned across the portfolio, with listings in Ontario, Alberta and B.C. for the first time. Management frames the technology as a moat: entry barriers, not just SKUs.

Borrowing at 13% rather than selling stock at the low

On October 29, after quarter-end, Avicanna raised $2 million in gross proceeds from a non-brokered private placement of debenture units at a 13% annual rate, maturing in a year, each unit carrying warrants struck at $0.20. The CEO was blunt about why: the equity price is not a price he is willing to sell at.

There's a disconnect in terms of the company's valuation and the reality of the company in terms of its fundamentals... we did not want to be further dilutive in this range. So with that, we felt much more comfortable taking a debt, and we're much more comfortable with our projections and the trajectory we have to be able to service that debt rather than be dilutive.

Aras Azadian, Founding CEO · 2026-11-12
It is a defensible trade for a company that has spent years conducting small placements, and he concedes the exhaustion: "it's not fun to conduct $0.5 million or $1 million private placements." But it also means a 13% coupon now sits on top of an operation that generated negative $691,000 of operating cash flow in the quarter. The refi clock starts in twelve months. And the contrast with prior calls is jarring. In April 2025, a long-time retail shareholder asked directly whether profitability would arrive in 2025: “Yes, we are quite confident within that... in terms of optimization and cost structures, we have completed what can be done. So, really, this year, the focus is on scale and growth.” — Aras Azadian, Chief Executive Officer · 2025-04-22 Profitability arrived a year late, and the "scale and growth" has so far produced a 10% revenue decline. The same call produced this: “I do believe that there is a potential for this company to be a $1 billion company.” — Aras Azadian, Chief Executive Officer · 2025-04-22 The market cap today is roughly $8 million. The CEO now attributes the all-time-low share price partly to two large shareholders exiting publicly in recent months, plus year-end tax-loss selling — a valuation argument that has been running for at least three calls without the tape ever agreeing.

The engine is MyMedi; the sector is no help

The genuine operating improvement is buried under the noise. The April 1 Veterans Affairs reimbursement cut slashed veteran patient reimbursement by 29%. Avicanna's revenue fell 10% against peer declines of 18% to 25%, because its patient base is unusually non-veteran and because it re-cut supplier terms and product mix mid-flight. Proprietary products rose to 31% of MyMedi platform sales from 19% a year ago — and from about 6% when it took over the Shoppers Drug Mart medical business — which matters because Avicanna earns both a wholesale and a retail margin on its own SKUs. The next leg is selling into medical institutions: three pilot partnerships embedding documentation into existing EMRs, pharmacist-led treatment planning, targeting the 99% of Canadians who use neither medical cannabis nor a physician-supervised cannabinoid regimen. Worth noting what has not changed: cannabinoid based medicine has been a top keyword every quarter since early 2025, and the U.S. rescheduling hope is now in its third consecutive vintage — “once we do eventually listen to the U.S. in terms of a senior exchange and the rescheduling of the United States takes place, that's going to open up the opportunity for more health care biotech investment.” — Aras Azadian, CEO, Founder · 2026-04-07 Same sentence, new year. The market backdrop offers nothing to lean on. The global top-75 keyword lists across the last twelve quarters are a wall of tariffs, IEEPA refunds, AI data centers, Fed hikes and fuel costs; cannabinoid medicine appears nowhere. Peer confluence in the last five days of reporters is effectively a single name — Auxly (XLY.TO), talking pre-roll innovation and dry flower — and the CEO himself cites Auxly as one of the rival brands performing well on MyMedi. The Canadian cannabis sector is still organised around adult-use flower; Avicanna's medical-plus-pharma construction is idiosyncratic, which cuts both ways when there is no sector tide. The honest read: a real product platform, a real cost reset, and a real reimbursement shock survived better than peers — financed by a tax credit and a one-year loan at 13%. The next two quarters decide whether QUIX listings convert into dollars and whether adjusted EBITDA can be positive in a quarter with no government rebate attached.